Overcoming Challenges in Treating Patients With Triple-Negative Breast Cancer
Stacy L. Moulder, MD, discusses the challenges in drug development for triple-negative breast cancer, specifically in the neoadjuvant setting.
Stacy L. Moulder, MD, professor of breast medical oncology at The University of Texas MD Anderson Cancer Center, discusses the challenges in drug development for triple-negative breast cancer (TNBC), specifically in the neoadjuvant setting.
Approximately 50% of patients with TNBC are sensitive to standard chemotherapy, says Moulder, and they do not need the additional toxicities of certain investigational agents.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
